At the end of 2021, S™☆₩"ynRx Therapeutics completed$  a PRE-A round of financing, whi®®∏ch was led by HaibangδαΩ✔ Fenghua Venture Capital  wiφ☆th a number of well-<σ"known investment institutions includi♠↕÷×ng Westlake Innovation Capita÷®σl in participation.

     Thi↑↑s round of financing is mainly utilized∏​¥λ for the establishment of the company&©®δ‍#39;s branch in Shan₩¥​ghai, the construction of→₩± laboratories , the product pipe∑ line development for each<×≥ project, and the in‍<troduction of high-educated domestic∞β© and foreign talents∏£.

    Founded in"α≠ August 2021, SynRx Theβ& ≥rapeutics is an innovatα©≈ive R&D company focusin↓∏β'g on the development of novel anti∑✘β-tumor drugs using synthetic l∑¶ethality approaches. We are currentl×£y exploring several first-in-class, ✔∞anti-tumor compounds, and$ < preclinical studies are in p&Ω→rogress .